Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 16 2022

Full Issue

Third Person — The First Woman — Appears To Be Cured Of HIV

A breakthrough stem-cell treatment has likely cured a patient of HIV, researchers revealed. While the treatment is not applicable for large populations, scientists say that it could open up possibilities for helping more people.

The Washington Post: A Middle-Aged Woman Is The Third Patient To Be Potentially Cured Of HIV, Scientists Report 

A middle-aged, mixed-race woman is the third patient to be potentially cured of HIV, with the virus in long-term remission four years after she received a transplant of stem cells harvested from an infant’s umbilical cord blood, scientists said Tuesday. The new case, reported at the annual meeting of the Conference on Retroviruses and Opportunistic Infection, is the first time the transplant approach has been successfully reported in a mixed-race woman, an advance that reinforces the exciting concept that an HIV cure may be possible in a wider array of people by using cord blood. (Johnson, 2/15)

ABC News: Breakthrough Treatment Makes Woman 3rd Person To Be Cured Of HIV

"This case is special for several reasons: First, our participant was a U.S. woman living with HIV of mixed race, who needed a stem cell transplant for treatment of her leukemia. And she would find a more difficult time finding both a genetic match and one with the HIV-resistant mutation to both cure her cancer and potentially her HIV. This is a natural, but rare mutation," said Dr. Yvonne Bryson, an infectious disease physician at UCLA who led the study. (Morrison and Salzman, 2/15)

The New York Times: A Woman Is Cured Of H.I.V. Using A Novel Treatment 

Cord blood is more widely available than the adult stem cells used in the bone marrow transplants that cured the previous two patients, and it does not need to be matched as closely to the recipient. Most donors in registries are of Caucasian origin, so allowing for only a partial match has the potential to cure dozens of Americans who have both H.I.V. and cancer each year, scientists said. The woman, who also had leukemia, received cord blood to treat her cancer. It came from a partially matched donor, instead of the typical practice of finding a bone marrow donor of similar race and ethnicity to the patient’s. She also received blood from a close relative to give her body temporary immune defenses while the transplant took. (Mandavilli, 2/15)

CNBC: Scientists Have Possibly Cured HIV In A Woman For The First Time

It is unethical, experts stress, to attempt an HIV cure through a stem cell transplant — a toxic, sometimes fatal procedure — in anyone who does not have a potentially fatal cancer or other condition that already makes them a candidate for such risky treatment. (Ryan, 2/15)

In other news about HIV/AIDS —

NBC News: Breakthrough HIV Reported In Injectable PrEP Trial; Experts Say Drug Still Very Effective

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their injections on schedule. The new findings indicate that, just as with those who take daily pills to prevent HIV, breakthrough infections are possible among people receiving Apretude. (Ryan, 2/15)

aidsmap: COVID-19 Vaccine Booster Produces Strong Responses In People With HIV With Low CD4 Counts

Booster doses of the Pfizer or Moderna vaccines revive antibody levels in people with HIV and response to a booster dose is not affected by CD4 count, Italian researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2022) this week. But at the conference's opening session, vaccine researcher Professor Dan Barouch questioned whether a strategy of relying on repeated boosters will be either necessary or feasible. He also called for a focus on the whole of the immune response, not just antibodies, when considering which vaccines to use and when boosters should be offered. (Alcorn, 2/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF